INTRODUCTION
Epilepsy in patients with brain tumours is common. The incidence of seizures varies from 20 to 70% with the highest incidence in low-grade gliomas (60-70%) 1 . There is an increasing use of systemic chemotherapy in patients with brain tumours, and this raises the concern on the potential of substantial interactions between AEDs and anti-neoplastic agents.
Phenytoin, carbamazepine, phenobarbital, and to a lesser extent valproate, oxcarbazepine and topiramate, are metabolised by the hepatic cytochrome P-450 system, especially the CYP 2C9, CYP 2C19, CYP 3A4 and CYP 2B1 iso-enzyme 2, 3 . To a more or lesser extent, all these AEDs have inductory or inhibitory effects on one or more iso-enzymes. Many chemotherapeutic agents also are metabolised by the hepatic CYP system 4 . Glucocorticoids are of special interest in patients with brain tumours. Dexamethasone is metabolised by CYP 3A4, and mostly induces it 5 .
Levetiracetam (LEV), a novel AED, has no known pharmacological interactions as it has no effect on mixed function oxidase liver enzymes and has no protein-binding properties 6 . Therefore, LEV may be a particularly useful drug in this group of patients. We performed a prospective feasibility study to evaluate the safety and efficacy of LEV in this patient group.
METHODS
Twenty-six patients with primary brain tumour participated in the study. Indications to start with LEV were: persisting seizures, adverse effects of other AEDs and/or potential drug interactions with anti-neoplastic agents or glucocorticoids. Patients with potential drug interactions and no seizures received LEV in a dose of 2000 mg/day; if needed, LEV was raised up to 3000 or 4000 mg/day in the presence of seizures. Efficacy of seizure control was defined as >50% seizure-reduction compared with seizure frequency before initiation of LEV. Adverse effects were recorded using standardised forms. Follow-up took part every 1-3 months. Patients with low-grade gliomas represented low-grade astrocytomas and oligodendrogliomas; patients with high-grade gliomas included anaplastic astrocytoma, glioblastoma multiforme and anaplastic oligodendrogliomas. Patients with newly diagnosed glioblastoma multiforme receiving systemic chemotherapy did so according to a protocol in which temozolomide was given concomitantly with radiation therapy.
RESULTS
A total of 18 patients with high-grade glioma and 8 with low-grade glioma took part in the study. In the low-grade glioma group, the most frequent indication to start LEV was persisting seizures. In the high-grade glioma group, the potential for drug interactions with systemic chemotherapy (temozolomide) and/or dexamethasone was a frequent indication. The median follow-up time was 9.3 months.
LEV was added to other AEDs in 25 patients. In 20 patients with persisting seizures, we found a seizure-reduction of >50% in 13 (65%) ( Table 1) . These patients were followed for a mean period of 11.8 months (median 12.8, range 3.5-20 months). In 7 of these 13 patients, the original drug could be stopped. One patient was started on monotherapy LEV as initial drug because of potential interactions. Treatment in this patient was successful during the follow-up period of 15 months. Of the 20 patients with persisting seizures 4 became totally seizure free. Adverse effects were observed in 9 patients (35%), occasionally more than one per patient. Most frequently reported adverse effects were fatigue, somnolence and dizziness and were usually mild. One patient developed a psychosis 4 weeks after starting LEV, leading to discontinuation of the drug. One patient developed a status epilepticus. No significant changes in blood chemistry were seen.
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Our conclusion is that treatment with LEV seems well feasible in brain tumours. Further investigation to the place of LEV as monotherapy in brain tumours seems warranted, including its effects in association with the use of chemotherapy.
